Compare iShares MSCI Hong Kong ETF (EWH) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Hong Kong ETF vs Heron Therapeutics Inc — how do they compare? iShares MSCI Hong Kong ETF trades at $22.06, while Heron Therapeutics Inc trades at $0.45 (market cap $84.50M). The key difference: iShares MSCI Hong Kong ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| EWH | HRTX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $24.55 | $2.02 |
52-Week Low | $20.15 | $0.39 |
Market Cap | — | $84.50M |
Enterprise Value | — | $182.40M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWH trades at $22.05, up 1.75% today, with a bullish technical signal from moving averages but overbought RSI readings. The ETF tracks Hong Kong equities, with recent momentum in Chinese tech stocks supporting performance. A dividend of $0.35 is scheduled for June 2026. Support and resistance cluster tightly around $22, indicating a critical price zone.
Outlook hinges on Hang Seng Index momentum and China's economic policies. Risks include regulatory scrutiny on Chinese firms and Asian market volatility. Analyst sentiment is mixed, with technical strength countered by valuation concerns in global markets.
HRTX trades at $0.44, up 2.63% today, with a bullish technical signal but bearish moving averages. The company reported Q1 2026 revenue of $151M with a net loss of $31M, maintaining a negative profit margin of -20.53%. Recent patent litigation developments and mixed earnings performance create uncertainty, though analyst consensus remains overwhelmingly positive with 94.7% buy ratings.
The outlook remains challenging with persistent losses and negative cash flow from operations, though improving net cash flow trends offer some optimism. Key risks include ongoing patent litigation and execution challenges in achieving profitability. The strong analyst support suggests potential upside if the company can deliver on its guidance and improve operational efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
